GlassScriptPhysician profile
Joel S Sellers
NPI 1710958517
$4,223.03
in general payments reported to CMS, 2019-2025
41 companies · $91.97 in 2025
The $91.97 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $765 · 2021: $1,087 · 2022: $1,068 · 2023: $509 · 2024: $111 · 2025: $91.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.15 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $434.25 | 2019-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $371.28 | 2019-2024 | Spravato |
| Abbott Laboratories | $367.88 | 2019-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $244.27 | 2019-2023 | Taltz, Olumiant |
| Novo Nordisk INC | $227.94 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $164.12 | 2021-2023 | Qulipta, Ubrelvy |
| Kowa Pharmaceuticals America, INC. | $137.47 | 2020-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $136.00 | 2020-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Fidia Pharma USA INC. | $124.05 | 2019-2022 | |
| Pacira Therapeutics, INC. | $104.88 | 2021 | |
| Amgen INC. | $104.67 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.91 | 2022-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $74.77 | 2021-2022 | |
| Djo, LLC | $72.80 | 2023-2025 | Cmf |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.